leadership team
Hanh Nguyen, PhD
Vice President, Head of Technical Ops

Hanh Nguyen, PhD serves as Vice President of Technical Operations with responsibility for Chemistry, Manufacturing and Control (CMC) and Clinical Supply Chain.

Hanh joined Morphic in 2019 after more than two decades in the biopharmaceutical industry with extensive experience from early pipeline development through therapeutic product commercialization. Prior to Morphic, she served as Head of Drug Product Development and Manufacturing for Epizyme and Forum. Hanh held positions of increasing responsibility, including as Head of Pre-formulation and Research at Sanofi, UK, and Manager of Formulation Development and Manufacturing at Biogen, US.

She has a PhD in Pharmaceutics from Sunderland University, UK and a Pharmacy degree from University of Medicine, Dentistry and Pharmacy in Ho Chi Minh City, Vietnam.

Back to Leadership Team
Scroll to Top

Contact Us

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.

αvβ8

Morphic is developing small molecule inhibitors of the integrin αvβ8 through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.